Skip to main content
NCBI home page
Food Science & Nutrition logoLink to Food Science & Nutrition
. 2023 Mar 13;11(6):2580–2588. doi: 10.1002/fsn3.3315

Effects of coenzyme Q10 supplementation on lipid profiles and liver enzymes of nonalcoholic fatty liver disease (NAFLD) patients: A systematic review and meta‐analysis of randomized controlled trials

Ali Ardekani 1, Reza Tabrizi 2,3, Elham Maleki 4, Kamran Bagheri Lankarani 1, Seyed Taghi Heydari 1, Mehdi Moradinazar 5, Maryam Akbari 1,✉
PMCID: PMC10261764  PMID: 37324909

Abstract

As an antioxidant, coenzyme Q 10 (CoQ10) has been proposed as a possible treatment for non‐alcoholic fatty liver disease (NAFLD). In the present meta‐analysis, we aimed to determine the effects of CoQ10 supplementation on lipid profiles and liver enzymes of NAFLD patients. We searched PubMed, Web of Science, Scopus, and Cochrane Library on 21 April 2022 to retrieve randomized controlled trials on NAFLD patients in which CoQ10 was utilized as a treatment. Data were pooled using the random‐effects model and weighted mean difference (WMD) was considered as the summary effect size. The analysis of the six included studies indicated an overall non‐significant decrease in the lipid profiles (total cholesterol (TC), low‐density lipoprotein cholesterol (LDL), high‐density lipoprotein cholesterol (HDL), and triglyceride (TG)), and liver enzymes (aspartate transaminase (AST), alanine transaminase (ALT), and gamma‐glutamyltransferase (GGT)) of NAFLD patients who received CoQ10. Sensitivity analysis using “leave‐one out” method showed a significant reduction in AST, and GGT after excluding certain studies. Also, subgroup analyses showed significant difference based on CoQ10 dose for TC, AST, and GGT, and also a significant decrease in AST based on the duration of the intervention. No publication bias was found between the studies. Although an overall non‐significant decrease was observed in lipid profiles and liver enzymes of NAFLD patients, the results of sensitivity and subgroup analyses showed significant effects of CoQ10 in certain conditions. Further RCTs should be done in light of our findings.

Keywords: antioxidants, coenzyme Q10, fatty liver, hyperlipidemias, liver function tests, non‐alcoholic fatty liver disease

In the present article, we investigated the effects of coenzyme Q10 supplementation on liver enzymes and lipid profiles of NAFLD patients.

graphic file with name FSN3-11-2580-g002.jpg

1. INTRODUCTION

The most frequent type of chronic liver disease is a non‐alcoholic fatty liver disease (NAFLD), which is notably prevalent in Western nations (Charlton, 2004; Masuoka & Chalasani, 2013). NAFLD encompasses an umbrella definition of a broad spectrum of clinical presentations, from simple uncomplicated steatosis to non‐alcoholic steatohepatitis (Farrell & Larter, 2006). During the past decades, alterations in human lifestyle have led to an increasing trend in obesity, high blood pressure, and type 2 diabetes mellitus (T2DM), all of which are risk factors for developing NAFLD (Godoy‐Matos et al., 2020; Zhao et al., 2020). According to a recent study, the worldwide prevalence of NAFLD from 1990 to 2019 increased from 21.9% to 37.3% (Le et al., 2021), which is notably high.

Although several meta‐analyses have indicated the potential benefits of a wide range of medicines and herbs such as green tea (Mansour‐Ghanaei et al., 2018), Nigella sativa (Tang et al., 2021), microbiome‐targeted therapies (Sharpton et al., 2019), Silymarin (Kalopitas et al., 2021), vitamin E (Amanullah et al., 2019), statins (Fatima et al., 2021), and some of the antidiabetic drugs (Lian & Fu, 2021), the treatment of NAFLD is still a matter of debate, and there are still no approved pharmacological treatments or prevention (Ferguson & Finck, 2021). Lifestyle modifications, weight loss through physical activity, and a healthy diet remain the core treatment of NAFLD (Cicero et al., 2018; Kenneally et al., 2017). Notably, antioxidants are suggested as a possible pharmacological treatment in previous studies (Mantovani & Dalbeni, 2021).

Coenzyme Q10 (CoQ10) is a lipid‐soluble antioxidant agent that may affect oxidative phosphorylation in mitochondria (Chokchaiwong et al., 2018; Testai et al., 2021). Previous investigations have revealed the possible role of CoQ10 in alleviating inflammation and cardiovascular diseases through its antioxidant effects (Hernández‐Camacho et al., 2018). Although poorly understood, it is hypothesized that CoQ10 could reduce lipid synthesis and help the oxidation of fatty acids through AMP‐activated protein kinase activation in the liver (Ke & Wenhua, 2019). Based on this hypothesis, studies were conducted to determine the possible therapeutic effects of CoQ10 in NAFLD patients, with mixed findings.

In the current investigation, we did a meta‐analysis on the randomized controlled trials (RCTs) of CoQ10 supplementation in NAFLD patients and investigated its effects on lipid profiles and liver enzymes after treatment.

2. METHODS

In conducting the present study, we utilized the “Preferred Reporting Items for Systematic Reviews and Meta‐Analyses” (PRISMA) statement (Page et al., 2021).

2.1. Search strategy

On 21st April 2022, we searched PubMed, Web of Science, Scopus, and Cochrane library databases using representative keywords and MeSH terms for “Coenzyme Q10” and “Non‐alcoholic fatty liver disease”. We searched Google Scholar to enhance our search's sensitivity. A forward and backward reference checking was also done for the included studies.

2.2. Screening process

We included RCTs on NAFLD patients (regardless of NAFLD grades) in which CoQ10 was used at least as a component of medications in the treatment group. No exclusion was posed based on year, language, or country of publication. Two independent authors evaluated the title and abstract of the studies after duplicate removal. Then, the remaining papers' full texts were evaluated based on the inclusion and exclusion criteria described above. Through contact with a third party, any disparities between authors were addressed throughout the screening process.

2.3. Data extraction and quality appraisal

The following data were extracted by two independent authors: first author's name, country, publication year, features of the study population, characteristics of intervention, and control groups before and after trial, including total cholesterol (TC), low‐density lipoprotein cholesterol (LDL), high‐density lipoprotein cholesterol (HDL), triglyceride (TG), aspartate transaminase (AST), alanine transaminase (ALT), and gamma‐glutamyltransferase (GGT). In addition, the quality of the studies was evaluated by two authors utilizing Cochrane Collaboration Risk of Bias tool (Higgins et al., 2011). In case of disagreements in the process of data extraction and quality appraisal, consultation with a third author was put forth.

2.4. Meta‐analysis

The effect sizes of CoQ10 supplementation on the changes of lipid profiles and liver enzymes were estimated. Effect sizes were assessed by using weighted mean difference (WMD) and its 95% CI and then pooling with random‐effects model.

In each article that did not report SD change, the following formula was applied to calculate the SD changes: “√[(SDpre^2 + SDpost^2)–(2 × r × SDpre × SDpost)]”. The r value as a correlation coefficient was estimated at 0.8 using the following formula from included studies that reported the SD change: “r = [(SDpre^2 + SDpost^2−SDchange^2)/(2 × SDpre × SDpost)]”. If merely standard error (SE) was given, SE was converted to SD by the formula: “SD = SE × √n”.

Inter‐study heterogeneity was evaluated using the Chi‐squared test (with p‐value <.1) and I 2 statistic (I 2 value >50%). Sensitivity analysis was done using the “leave one out” method. Also, subgroup analyses were utilized to detect the source of heterogeneity. Egger's regression and Begg's rank correlation tests were statistically used to assess the evidence of small‐study effects among included trials. STATA version 16.0 (Stata Corp., College Station, TX) and Comprehensive Meta‐analysis (CMA) Version 2.0 were used for all statistical analyses.

3. RESULTS

3.1. Literature search and quality appraisal

Searching through the databases, we found 823 studies. Finally, after duplicate removal and the screening process, six studies (Curcio et al., 2020; Farhangi et al., 2014; Farsi et al., 2016; Jafarvand et al., 2016; Mohammadshahi et al., 2014; Shafieipour et al., 2018) satisfied the criteria for inclusion in the meta‐analysis (Figure 1). The features of the included RCTs are represented in Table 1. The results of the risk of bias assessment are depicted in Figure 2.

FIGURE 1.

FIGURE 1

Open in a new tab

Screening and selection flowchart.

TABLE 1.

Summary of the included studies.

First author Country Population target Type intervention Type control Duration of intervention Intervention/control group
Farhangi et al. (2014) Iran NAFLD patients 100 mg oral CoQ10 daily Placebo daily 4 weeks 20/21
Farsi et al. (2016) Iran NAFLD patients 100 mg oral CoQ10 daily Placebo daily 12 weeks 20/21
Jafarvand et al. (2016) Iran NAFLD patients 100 mg oral CoQ10 daily Placebo daily 4 weeks 20/21
Mohammadshahi et al. (2014) Iran NAFLD patients 100 mg oral CoQ10 daily Placebo daily 12 weeks 20/21
Shafieipour et al. (2018) Iran NAFLD patients 60 mg CoQ10 daily + lifestyle modification Vitamin E 800 IU daily + lifestyle modification 12 weeks 30/25
Curcio et al. (2020) Italy Mild to severe NAFLD patients 2 capsules a day containing silymarin, vitamin C, vitamin E, coenzyme Q10 (20 mg), and selenomethionine +recommendations for lifestyle modification Only recommendations for lifestyle modification 12 weeks 41/40
Open in a new tab

FIGURE 2.

FIGURE 2

Open in a new tab

Details of risk of bias assessment.

3.2. The effects of CoQ10 on NAFLD

The effects of CoQ10 supplementation on lipid profiles and liver enzymes are shown in Figures 3 and 4. The analysis showed a non‐significant decrease in the lipid profile including TC [WMD = −6.4 mg/dL; 95% CI, −20.91; 8.09, p = .39; I 2 = 80.37%], LDL [WMD = −2.28 mg/dL; 95% CI, −13.05; 8.5, p = .68; I 2 = 82.58%], HDL [WMD = −0.38 mg/dL; 95% CI, −2.72; 1.97, p = .75; I 2 = 53.45%], and TG [WMD = −17.9 mg/dL; 95% CI, −43.83; 7.86, p = .17; I 2 = 70.33%] in the CoQ10 group compared to control group.

FIGURE 3.

FIGURE 3

Open in a new tab

The effects of CoQ10 supplementation on lipid profiles of the NAFLD patients.

FIGURE 4.

FIGURE 4

Open in a new tab

The effects of CoQ10 supplementation on liver enzymes of the NAFLD patients.

A non‐significant decrease was observed in the WMD of liver enzymes in the CoQ10 group in comparison with control group: AST [WMD = −6.03 U/L; 95% CI, −12.39; 0.32, p = .06; I 2 = 89.66%], ALT [WMD = −6.01 U/L; 95% CI, −15.49; 3.46, p = .21; I 2 = 92.3%], GGT [WMD = −18.95 U/L; 95% CI, −43.54; 5.63, p = .13; I 2 = 97.55%].

3.3. Subgroup analysis

In the subgroup analysis, we found significant effects of CoQ10 supplementation on lowering TC [WMD = −17.17 mg/dL; 95% CI, −30.76; −3.57, p = .013; I 2 = 58.13%] with <100 mg dose, and in “CoQ10 + other drugs” subgroups; however, this decrease was observed in AST [WMD = −2.12; 95% CI, −3.72; −0.52, p = .009; I 2 = 11.60%] and GGT [WMD = −5.67; 95% CI, −9.58; −1.76, p = .004] with ≥100 mg CoQ10 per day, and in “CoQ10 only” subgroups. Also, AST reduction [WMD = −1.64; 95% CI, −2.98; −0.30, p = .01; I 2 = 92.65%] was statistically significant in 4‐week intervention group (Table 2).

TABLE 2.

Subgroup analyses for liver enzymes and lipid profiles.

Variables Subgroup Study WMD (95% CI) p I 2 (%)
TC
Duration 12 weeks 3 −8.33 (−27.3, 10.63) .38 84.65
4 weeks 1 −0.2 (−13.31, 12.91) .97 –
Dosage <100 mg 2 −17.17 (−30.76, −3.57) .013 58.13
≥100 mg 2 3.89 (−5.72, 13.51) .427 0.0
Type of intervention CoQ10 only 2 3.89 (−5.72, 13.51) .427 0.0
CoQ10 + other drugs 2 −17.17 (−30.76, −3.57) .013 58.13
LDL
Duration 12 weeks 3 −3.19 (−16.75, 10.35) .64 87.32
4 weeks 1 1.2 (−10.46, 12.86) .84 –
Dosage <100 mg 2 −6.43 (−24.32, 11.45) .48 90.31
≥100 mg 2 2.73 (−4.77, 10.24) .47 0.0
Type of intervention CoQ10 only 2 2.73 (−4.77, 10.24) .47 0.0
CoQ10 + other drugs 2 −6.43 (−24.32, 11.45) .48 90.31
HDL
Duration 12 weeks 3 −0.45 (−3.51, 2.59) .76 68.97
4 weeks 1 −0.2 (−4.43, 4.03) .92 –
Dosage <100 mg 2 0.12 (−4.48, 4.72) .95 79.96
≥100 mg 2 −1.22 (−3.70, 1.24) .33 0.0
Type of intervention CoQ10 only 2 −1.22 (−3.70, 1.24) .33 0.0
CoQ10 + other drugs 2 0.12 (−4.48, 4.72) .95 79.96
TG
Duration 12 weeks 3 −25.25 (−55.35, 4.84) .10 63.82
4 weeks 1 −0.8 (−22.59, 20.99) .94 –
Dosage <100 mg 2 −28.31 (−77.90, 21.27) .26 72.93
≥100 mg 2 −6.12 (−23.40, 11.14) .48 0.0
Type of intervention CoQ10 only 2 −6.12 (−23.40, 11.14) .26 0.0
CoQ10 + other drugs 2 −28.31 (−77.90, 21.27) .48 72.93
AST
Duration 12 weeks 3 −9.26 (−25.85, 7.33) .27 92.65
4 weeks 2 −1.64 (−2.98, −0.30) .01 0.0
Dosage <100 mg 2 −11.23 (−42.89, 20.43) .48 94.23
≥100 mg 3 −2.12 (−3.72, −0.52) .009 11.60
Type of intervention CoQ10 only 3 −2.12 (−3.72, −0.52) .009 11.60
CoQ10 + other drugs 2 −11.23 (−42.89, 20.43) .48 94.23
ALT
Duration 12 weeks 3 −10.72 (−28.47, 7.02) .23 90.5
4 weeks 2 1.74 (0.03, 3.44) .04 0.0
Dosage <100 mg 2 −11.65 (−46.40, 23.10) .51 90.82
≥100 mg 3 −1.55 (−7.34, 4.22) .59 79.93
Type of intervention CoQ10 only 3 −1.55 (−7.34, 4.22) .59 79.93
CoQ10 + other drugs 2 −11.65 (−46.40, 23.10) .51 90.82
GGT
Duration 12 weeks 3 −18.95 (−43.53, 5.63) .13 97.55
4 weeks – – – –
Dosage <100 mg 2 −25.76 (−60.37, 8.85) .14 96.95
≥100 mg 1 −5.67 (−9.58, −1.76) .004 –
Type of intervention CoQ10 only 1 −5.67 (−9.58, −1.76) .004 –
CoQ10 + other drugs 2 −25.76 (−60.37, 8.85) .14 96.95
Open in a new tab

Note: Bold values are statistically significant reduction.

3.4. Sensitivity analysis and publication bias

According to the sensitivity analysis, for AST after removing the study by Shafieipour et al. (WMD = −7.67; 95% CI, −14.57; −0.78) or Curcio et al. (WMD = −2.06; 95% CI, −3.83; −0.29), the results became significant. For GGT, after removing the study by Curcio et al. (WMD; −5.99; 95% CI, −9.61; −2.36), the results showed a significant effect. No significant difference was observed after removing each study from the pooled analysis for TC, LDL, HDL, TG, and ALT (File S1). Moreover, no publication bias was observed according to Egger's regression and Begg's rank correlation tests. Funnel plots of publication bias are available in File S2.

4. DISCUSSION

This is the first meta‐analysis on the effects of CoQ10 supplementation on NAFLD patients. In the present study, a statistically non‐significant decrease was observed in patients' AST, ALT, GGT, TC, LDL, HDL, and TG after treatment with CoQ10. However, according to the sensitivity and subgroup analyses, this reduction could be statistically significant in certain circumstances.

The hepatoprotective effects of CoQ10 have been reported in previous animal studies (Ashkani Esfahani et al., 2013; Choi et al., 2009; Jiménez‐Santos et al., 2014; Sohet et al., 2009), emphasizing the possibility of reduction in liver enzymes and inflammatory markers after treatment with CoQ10 (Perumpail et al., 2018). In line with their results, Farsi et al. (Farsi et al., 2016) by ultrasonographic evaluation of NAFLD patients before and after treatment found a significant improvement in the intervention group who received CoQ10. However, the mentioned study was the only study that investigated NAFLD grades after treatment. In our subgroup analysis, a significant reduction was observed in AST and GGT values of the patients who received at least 100 mg of CoQ10 per day. More studies are needed to evaluate both ultrasonographic grades and laboratory markers of NAFLD patients to determine the effects of CoQ10.

The interrelation between obesity and NAFLD has been suggested to be mediated by blood levels of lipids. Steatosis develops when the amount of liver fatty acid absorption from blood and de novo fatty acid synthesis exceeds their rate of oxidation and export (Fabbrini et al., 2010). In this regard, attenuated adiposity has been proposed as the mechanism by which CoQ10 may ameliorate NAFLD severity (Chen et al., 2019). Previous studies on animals indicated inconclusive outcomes of coenzyme Q supplementation on NAFLD (Botham et al., 2015). Similarly, in our meta‐analysis, a non‐significant decrease was observed among the patients who received CoQ10. However, given the paucity of studies, we strongly recommend further investigating CoQ10 supplementation in high‐quality RCTs with larger sample sizes.

Also, the duration of the intervention may be a key factor in determining the effectiveness of CoQ10; in an animal study that reported positive results, the course of the treatment was 24 weeks (Chen et al., 2019), while according to Table 2 in human studies, the duration of the treatment ranged from 4 to 12 weeks which yielded in mixed results. Further studies with longer intervention duration are recommended to clarify the impact of time.

According to the subgroup analysis, prescribing different dosages of CoQ10 may lead to different outcomes in NAFLD patients. CoQ10 has been utilized in a wide range of diseases like cardiovascular disorders, diabetes, Parkinson's disease, and mitochondrial cytopathies. The recommended dose of CoQ10 usually ranged from 50 mg to over 200 mg per day (Bonakdar & Guarneri, 2005). Comparative studies using different dosages of CoQ10 are needed to determine its lowering effects on liver enzymes and lipids. Also, as Crucio et al. (Curcio et al., 2020) utilized in their study, combination therapy of antioxidants, vitamins, and herbs, which has shown to be possibly effective in other studies, may be an effective strategy that should be further investigated in NAFLD patients.

We conducted the present meta‐analysis on RCTs with a standard protocol according to the PRISMA statement; however, it is not free of limitations. The paucity of studies and small sample sizes should be considered when interpreting the data. Also, most of the studies were from Iran, and one study was from Italy, which encompasses a narrow range of ethnicities. Furthermore, in one of the studies (Curcio et al., 2020), other minerals and vitamins were combined with CoQ10 in the intervention group, and in one study (Shafieipour et al., 2018) the control group received vitamin E.

5. CONCLUSION

Overall, a statistically non‐significant decrease was observed in lipid profiles and liver enzymes of NAFLD patients after treatment with CoQ10. However, the results of sensitivity and subgroup analyses indicated significant effects in certain circumstances. Further RCTs with large sample sizes using different dosages of CoQ10 in different intervention courses are required to establish a clearer picture of this topic.

CONFLICT OF INTEREST STATEMENT

None.

Supporting information

File S1.

Click here for additional data file. (223.8KB, docx)

File S2.

Click here for additional data file. (42.6KB, docx)

ACKNOWLEDGMENTS

None.

Ardekani, A. , Tabrizi, R. , Maleki, E. , Bagheri Lankarani, K. , Heydari, S. T. , Moradinazar, M. , & Akbari, M. (2023). Effects of coenzyme Q10 supplementation on lipid profiles and liver enzymes of nonalcoholic fatty liver disease (NAFLD) patients: A systematic review and meta‐analysis of randomized controlled trials. Food Science & Nutrition, 11, 2580–2588. 10.1002/fsn3.3315

DATA AVAILABILITY STATEMENT

The data supporting the current study are available upon reasonable request from the corresponding author.

REFERENCES

  1. Amanullah, I. , Khan, Y. H. , Anwar, I. , Gulzar, A. , Mallhi, T. H. , & Raja, A. A. (2019). Effect of vitamin E in non‐alcoholic fatty liver disease: A systematic review and meta‐analysis of randomised controlled trials. Postgraduate Medical Journal, 95(1129), 601–611. [DOI] [PubMed] [Google Scholar]
  2. Ashkani Esfahani, S. , Esmaeilzadeh, E. , Bagheri, F. , Emami, Y. , & Farjam, M. (2013). The effect of co‐enzyme q10 on acute liver damage in rats, a biochemical and pathological study. Hepatitis Monthly, 13(8), e13685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bonakdar, R. A. , & Guarneri, E. (2005). Coenzyme Q10. American Family Physician, 72(6), 1065–1070. [PubMed] [Google Scholar]
  4. Botham, K. M. , Napolitano, M. , & Bravo, E. (2015). The emerging role of disturbed CoQ metabolism in nonalcoholic fatty liver disease development and progression. Nutrients, 7(12), 9834–9846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Charlton, M. (2004). Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clinical Gastroenterology and Hepatology, 2(12), 1048–1058. [DOI] [PubMed] [Google Scholar]
  6. Chen, K. , Chen, X. , Xue, H. , Zhang, P. , Fang, W. , Chen, X. , & Ling, W. (2019). Coenzyme Q10 attenuates high‐fat diet‐induced non‐alcoholic fatty liver disease through activation of the AMPK pathway. Food & Function, 10(2), 814–823. [DOI] [PubMed] [Google Scholar]
  7. Choi, H. K. , Pokharel, Y. R. , Lim, S. C. , Han, H. K. , Ryu, C. S. , Kim, S. K. , Kwak, M. K. , & Kang, K. W. (2009). Inhibition of liver fibrosis by solubilized coenzyme Q10: Role of Nrf2 activation in inhibiting transforming growth factor‐beta1 expression. Toxicology and Applied Pharmacology, 240(3), 377–384. [DOI] [PubMed] [Google Scholar]
  8. Chokchaiwong, S. , Kuo, Y. T. , Lin, S. H. , Hsu, Y. C. , Hsu, S. P. , Liu, Y. T. , Chou, A. J. , & Kao, S. H. (2018). Coenzyme Q10 serves to couple mitochondrial oxidative phosphorylation and fatty acid β‐oxidation, and attenuates NLRP3 inflammasome activation. Free Radical Research, 52(11–12), 1445–1455. [DOI] [PubMed] [Google Scholar]
  9. Cicero, A. F. G. , Colletti, A. , & Bellentani, S. (2018). Nutraceutical approach to non‐alcoholic fatty liver disease (NAFLD): The available clinical evidence. Nutrients, 10(9), 1153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Curcio, A. , Romano, A. , Cuozzo, S. , Nicola, A. D. , Grassi, O. , Schiaroli, D. , Nocera, G. F. , & Pironti, M. (2020). Silymarin in combination with vitamin C, vitamin E, coenzyme Q10 and Selenomethionine to improve liver enzymes and blood lipid profile in NAFLD patients. Medicina (Kaunas), 56(10), 544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fabbrini, E. , Sullivan, S. , & Klein, S. (2010). Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology, 51(2), 679–689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Farhangi, M. A. , Alipour, B. , Jafarvand, E. , & Khoshbaten, M. (2014). Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: Effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress. Archives of Medical Research, 45(7), 589–595. [DOI] [PubMed] [Google Scholar]
  13. Farrell, G. C. , & Larter, C. Z. (2006). Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology, 43(S1), S99–S112. [DOI] [PubMed] [Google Scholar]
  14. Farsi, F. , Mohammadshahi, M. , Alavinejad, P. , Rezazadeh, A. , Zarei, M. , & Engali, K. A. (2016). Functions of coenzyme Q10 supplementation on liver enzymes, markers of systemic inflammation, and adipokines in patients affected by nonalcoholic fatty liver disease: A double‐blind, placebo‐controlled, randomized clinical trial. Journal of the American College of Nutrition, 35(4), 346–353. [DOI] [PubMed] [Google Scholar]
  15. Fatima, K. , Moeed, A. , Waqar, E. , Raafe Atif, A. , Kamran, A. , Rizvi, H. , Fatima Suri, N. , Haider, H. , Hasan Shuja, S. , Khalid, M. , & Khan Minhas, A. M. (2021). Efficacy of statins in treatment and development of non‐alcoholic fatty liver disease and steatohepatitis: A systematic review and meta‐analysis. Clinics and Research in Hepatology and Gastroenterology, 46(4), 101816. [DOI] [PubMed] [Google Scholar]
  16. Ferguson, D. , & Finck, B. N. (2021). Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nature Reviews Endocrinology, 17(8), 484–495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Godoy‐Matos, A. F. , Silva Júnior, W. S. , & Valerio, C. M. (2020). NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetology & Metabolic Syndrome, 12, 60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hernández‐Camacho, J. D. , Bernier, M. , López‐Lluch, G. , & Navas, P. (2018). Coenzyme Q(10) supplementation in aging and disease. Frontiers in Physiology, 9, 44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Higgins, J. P. T. , Altman, D. G. , Gotzsche, P. C. , Juni, P. , Moher, D. , Oxman, A. D. , Savovic, J. , Schulz, K. F. , Weeks, L. , Sterne, J. A. C. , & Cochrane Bias Methods Group, Cochrane Statistical Methods Group . (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, d5928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Jafarvand, E. , Farhangi, M. A. , Alipour, B. , & Khoshbaten, M. (2016). Effects of coenzyme Q10 supplementation on the anthropometric variables, lipid profiles and liver enzymes in patients with non‐alcoholic fatty liver disease. Bangladesh Journal of Pharmacology, 11(1), 35–42. [Google Scholar]
  21. Jiménez‐Santos, M. A. , Juárez‐Rojop, I. E. , Tovilla‐Zárate, C. A. , Espinosa‐García, M. T. , Juárez‐Oropeza, M. A. , Ramón‐Frías, T. , Bermúdez‐Ocaña, D. Y. , & Díaz‐Zagoya, J. C. (2014). Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol‐rich diet. Lipids in Health and Disease, 13(1), 22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kalopitas, G. , Antza, C. , Doundoulakis, I. , Siargkas, A. , Kouroumalis, E. , Germanidis, G. , Samara, M. , & Chourdakis, M. (2021). Impact of silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta‐analysis. Nutrition, 83, 111092. [DOI] [PubMed] [Google Scholar]
  23. Ke, C. , & Wenhua, L. (2019). Coenzyme Q10 attenuates high‐fat diet‐induced non‐alcoholic fatty liver disease through activation of AMPK pathway (P06‐060‐19). Current Developments in Nutrition, 3(Supplement_1), nzz031.P06‐060‐19. [Google Scholar]
  24. Kenneally, S. , Sier, J. H. , & Moore, J. B. (2017). Efficacy of dietary and physical activity intervention in non‐alcoholic fatty liver disease: A systematic review. BMJ Open Gastroenterology, 4(1), e000139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Le, M. H. , Yeo, Y. H. , Li, X. , Li, J. , Zou, B. , Wu, Y. , Ye, Q. , Huang, D. Q. , Zhao, C. , Zhang, J. , Liu, C. , Chang, N. , Xing, F. , Yan, S. , Wan, Z. H. , Tang, N. S. Y. , Mayumi, M. , Liu, X. , Liu, C. , … Nguyen, M. H. (2021). 2019 global NAFLD prevalence: A systematic review and meta‐analysis. Clinical Gastroenterology and Hepatology, 20, 2809–2817.e28. [DOI] [PubMed] [Google Scholar]
  26. Lian, J. , & Fu, J. (2021). Efficacy of various hypoglycemic agents in the treatment of patients with nonalcoholic liver disease with or without diabetes: A network meta‐analysis. Frontiers in Endocrinology, 12, 12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mansour‐Ghanaei, F. , Hadi, A. , Pourmasoumi, M. , Joukar, F. , Golpour, S. , & Najafgholizadeh, A. (2018). Green tea as a safe alternative approach for nonalcoholic fatty liver treatment: A systematic review and meta‐analysis of clinical trials. Phytotherapy Research, 32(10), 1876–1884. [DOI] [PubMed] [Google Scholar]
  28. Mantovani, A. , & Dalbeni, A. (2021). Treatments for NAFLD: State of art. International Journal of Molecular Sciences, 22(5), 2350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Masuoka, H. C. , & Chalasani, N. (2013). Nonalcoholic fatty liver disease: An emerging threat to obese and diabetic individuals. Annals of the New York Academy of Sciences, 1281(1), 106–122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Mohammadshahi, M. , Farsi, F. , Alavi Nejad, P. , Hajiani, E. , Zarei, M. , & Engali, K. A. (2014). The coenzyme Q10 supplementation effects on lipid profile, fasting blood sugar, blood pressure and oxidative stress status among non‐alcoholic fatty liver disease patients: A randomized, placebo‐controlled, pilot study. Journal of Gastroenterology and Hepatology Research, 3(6), 1108–1113. [Google Scholar]
  31. Page, M. J. , McKenzie, J. E. , Bossuyt, P. M. , Boutron, I. , Hoffmann, T. C. , Mulrow, C. D. , Shamseer, L. , Tetzlaff, J. M. , Akl, E. A. , Brennan, S. E. , Chou, R. , Glanville, J. , Grimshaw, J. M. , Hróbjartsson, A. , Lalu, M. M. , Li, T. , Loder, E. W. , Mayo‐Wilson, E. , McDonald, S. , … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Systematic Reviews, 10(1), 89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Perumpail, B. J. , Li, A. A. , Iqbal, U. , Sallam, S. , Shah, N. D. , Kwong, W. , Cholankeril, G. , Kim, D. , & Ahmed, A. (2018). Potential therapeutic benefits of herbs and supplements in patients with NAFLD. Diseases, 6(3), 80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Shafieipour, S. , Bahari, A. , Hashemi, M. , & Hashemzehi, N. (2018). Effects of coenzyme Q10 on biochemical markers of hepatic necroinflammation in patients with nonalcoholic fatty liver. International Journal of Drug Development and Research, 10(2), 12–16. [Google Scholar]
  34. Sharpton, S. R. , Maraj, B. , Harding‐Theobald, E. , Vittinghoff, E. , & Terrault, N. A. (2019). Gut microbiome‐targeted therapies in nonalcoholic fatty liver disease: A systematic review, meta‐analysis, and meta‐regression. The American Journal of Clinical Nutrition, 110(1), 139–149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sohet, F. M. , Neyrinck, A. M. , Pachikian, B. D. , de Backer, F. C. , Bindels, L. B. , Niklowitz, P. , Menke, T. , Cani, P. D. , & Delzenne, N. M. (2009). Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet‐induced obesity in mice. Biochemical Pharmacology, 78(11), 1391–1400. [DOI] [PubMed] [Google Scholar]
  36. Tang, G. , Zhang, L. , Tao, J. , & Wei, Z. (2021). Effect of Nigella sativa in the treatment of nonalcoholic fatty liver disease: A systematic review and meta‐analysis of randomized controlled trials. Phytotherapy Research, 35(8), 4183–4193. [DOI] [PubMed] [Google Scholar]
  37. Testai, L. , Martelli, A. , Flori, L. , Cicero, A. F. G. , & Colletti, A. (2021). Coenzyme Q(10): Clinical applications beyond cardiovascular diseases. Nutrients, 13(5), 1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Zhao, Y.‐C. , Zhao, G. J. , Chen, Z. , She, Z. G. , Cai, J. , & Li, H. (2020). Nonalcoholic fatty liver disease. Hypertension, 75(2), 275–284. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

File S1.

Click here for additional data file. (223.8KB, docx)

File S2.

Click here for additional data file. (42.6KB, docx)

Data Availability Statement

The data supporting the current study are available upon reasonable request from the corresponding author.

Articles from Food Science & Nutrition are provided here courtesy of Wiley

RESOURCES